Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26546966
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Brain+Res
2016 ; 1638
(Pt B
): 209-220
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Oligodendrocyte progenitor programming and reprogramming: Toward myelin
regeneration
#MMPMID26546966
Lopez Juarez A
; He D
; Richard Lu Q
Brain Res
2016[May]; 1638
(Pt B
): 209-220
PMID26546966
show ga
Demyelinating diseases such as multiple sclerosis (MS) are among the most
disabling and cost-intensive neurological disorders. The loss of myelin in the
central nervous system, produced by oligodendrocytes (OLs), impairs saltatory
nerve conduction, leading to motor and cognitive deficits. Immunosuppression
therapy has a limited efficacy in MS patients, arguing for a paradigm shift to
strategies that target OL lineage cells to achieve myelin repair. The inhibitory
microenvironment in MS lesions abrogates the expansion and differentiation of
resident OL precursor cells (OPCs) into mature myelin-forming OLs. Recent studies
indicate that OPCs display a highly plastic ability to differentiate into
alternative cell lineages under certain circumstances. Thus, understanding the
mechanisms that maintain and control OPC fate and differentiation into mature OLs
in a hostile, non-permissive lesion environment may open new opportunities for
regenerative therapies. In this review, we will focus on 1) the plasticity of
OPCs in terms of their developmental origins, distribution, and differentiation
potentials in the normal and injured brain; 2) recent discoveries of extrinsic
and intrinsic factors and small molecule compounds that control OPC specification
and differentiation; and 3) therapeutic potential for motivation of neural
progenitor cells and reprogramming of differentiated cells into OPCs and their
likely impacts on remyelination. OL-based therapies through activating
regenerative potentials of OPCs or cell replacement offer exciting opportunities
for innovative strategies to promote remyelination and neuroprotection in
devastating demyelinating diseases like MS. This article is part of a Special
Issue entitled SI:NG2-glia(Invited only).